Intermittent Fasting induced ketogenesis inhibits mouse epithelial ovarian tumors by promoting anti-tumor T cell response.


Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
10 Mar 2023
Historique:
pubmed: 23 3 2023
medline: 23 3 2023
entrez: 22 3 2023
Statut: epublish

Résumé

Epithelial Ovarian Cancer (EOC) is the most lethal gynecologic cancer with limited genetic alterations identified that can be therapeutically targeted. In tumor bearing mice, short-term fasting, fasting mimicking diet and calorie restriction enhance the activity of antineoplastic treatment by modulating systemic metabolism and boosting anti-tumor immunity. We tested the outcome of sixteen-hour intermittent fasting (IF) on mouse EOC progression with focus on fasting driven antitumor immune responses. IF resulted in consistent decrease of tumor promoting metabolic growth factors and cytokines, recapitulating changes that creates a tumor antagonizing environment. Immune profiling revealed that IF profoundly reshapes anti-cancer immunity by inducing increase in CD4

Identifiants

pubmed: 36945428
doi: 10.1101/2023.03.08.531740
pmc: PMC10028914
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : R01 CA249188
Pays : United States

Commentaires et corrections

Type : UpdateIn

Déclaration de conflit d'intérêts

Conflict of Interest: We have no conflict or potential competing conflicts.

Auteurs

Mary Priyanka Udumula (MP)

Department of Women's Health Services, Henry Ford Hospital and Henry Ford Cancer Institute, Detroit, MI.

Harshit Singh (H)

Department of Women's Health Services, Henry Ford Hospital and Henry Ford Cancer Institute, Detroit, MI.

Rashid Faraz (R)

Metabolomics Core, Department of Neurology, Henry Ford Hospital, Detroit, MI 48202.

Laila Poisson (L)

Department of Public Health Services and Center for Bioinformatics and Henry Ford Cancer Institute, Detroit, MI.

Nivedita Tiwari (N)

Department of Women's Health Services, Henry Ford Hospital and Henry Ford Cancer Institute, Detroit, MI.

Irina Dimitrova (I)

Department of Women's Health Services, Henry Ford Hospital and Henry Ford Cancer Institute, Detroit, MI.

Miriana Hijaz (M)

Department of Women's Health Services, Henry Ford Hospital and Henry Ford Cancer Institute, Detroit, MI.

Radhika Gogoi (R)

Department of Gynecology Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State University, Detroit, MI.

Margaret Swenor (M)

Department of Lifestyle and Functional Medicine, Henry Ford Hospital and Henry Ford Cancer Institute, Detroit, MI.

Adnan Munkarah (A)

Department of Women's Health Services, Henry Ford Hospital and Henry Ford Cancer Institute, Detroit, MI.

Shailendra Giri (S)

Metabolomics Core, Department of Neurology, Henry Ford Hospital, Detroit, MI 48202.

Ramandeep Rattan (R)

Department of Women's Health Services, Henry Ford Hospital and Henry Ford Cancer Institute, Detroit, MI.
Department of Oncology, Wayne State University, Detroit, MI.

Classifications MeSH